Team

Dr. Krueger is at The Rockefeller University in New York City where he serves as its Chief Executive Officer, the Head of the Laboratory for Investigative Dermatology, and a Senior Attending Physician and Co-director for the hospital’s Center for Clinical and Translational Science. His research group at Rockefeller was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis, establishing that elimination of pathogenic T cells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways and to conduct parallel biomarker studies that define mechanisms of targeted therapeutics in human populations. His group discovered elevated expression of IL-23 in psoriasis lesions and the contribution of this cytokine to an inflammatory axis dominated by Th17 T-cells. This work has also provided the “disease maps” for cytokine-driven inflammation in psoriasis, which has been the basis for biologic therapeutic development for the disease. The successful development of multiple therapeutic antagonists to IL-12/23, IL-23/IL-39, and IL-17 extends from this research and early clinical trials conducted by his group. Dr. Krueger received an A.B. in Biochemistry from Princeton University, a Ph.D. in Virology and Cell Biology from The Rockefeller University, and an M.D. from Cornell University Medical College, where he also completed an internship in internal medicine and residency in dermatology. Dr. Krueger is certified by the American Board of Dermatology and has published hundreds of papers in notable scientific journals.